 |
|
|
|
Media Center Overview
|
Press Releases
|
|
|
2010 Press Releases
2009 Press Releases
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
2009 Press Releases
| |
December 17, 2009
Dean Mitchell Appointed to Talecris Board of Directors
|
| |
November 10, 2009
Talecris Biotherapeutics Announces Third Quarter 2009 Results
|
| |
October 30, 2009
Talecris Biotherapeutics to Report Third Quarter 2009 Financial Results
|
| |
October 21, 2009
Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
|
| |
October 16, 2009
Talecris Biotherapeutics Announces Pricing of $600 Million Senior Notes due 2016
|
| |
October 15, 2009
The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc
|
| |
October 13, 2009
Talecris Biotherapeutics Announces Private Offering of $550 Million Senior Notes due 2016
|
| |
October 07, 2009
Talecris Announces Closing of Initial Public Offering and Exercise of Over - Allotment Option
|
| |
September 30, 2009
Talecris Biotherapeutics Prices Initial Public Offering of Common Stock at $19.00 Per Share
|
| |
September 15, 2009
Talecris Commences Initial Public Offering of Common Stock
|
| |
June 09, 2009
Talecris Biotherapeutics Receives Orphan Drug Designation for Plasmin (Human) to Treat Acute Peripheral Arterial Occlusion
|
| |
June 04, 2009
Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant
|
| |
May 28, 2009
Talecris Responds to U.S. Federal Trade Commission Filing of Complaint to Challenge Proposed CSL Transaction
|
| |
May 18, 2009
Talecris Presents New Data from Phase III Studies of a More Concentrated Formulation of Prolastin® to Treat AAT Deficiency
|
| |
April 23, 2009
New Publication of Landmark Study Demonstrates Gamunex® Improves Health-Related Quality of Life in Patients with CIDP
|
| |
February 09, 2009
Talecris Biotherapeutics, Inc. Names its 2009 Talents Grant Recipients
|
| |
February 05, 2009
Thrombate III® Approved for Room Temperature Storage
|
2008 Press Releases
| |
November 18, 2008
The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
|
| |
October 15, 2008
Talecris Biotherapeutics Helps Patients Receive Gamunex® During Lapses in Private Insurance Coverage
|
| |
October 14, 2008
Health Canada Grants Approval to Talecris Biotherapeutics for Gamunex as a Treatment for Neurological Disorder CIDP in Canada
|
| |
September 23, 2008
Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response in Some Patients with CIDP
|
| |
September 23, 2008
Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve Physical and Social Functioning In CIDP Patients
|
| |
September 18, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics, Inc. Expand Diagnostic Services for Primary Immunodeficiencies at Children's Hospital Boston
|
| |
September 15, 2008
FDA Grants Approval to Talecris Biotherapeutics for Gamunex® as a Treatment for Neurological Disorder CIDP in the United States
|
| |
September 12, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Children's Medical Center
|
| |
August 20, 2008
Frankfurt University Hospital opens Hessen’s First Centre for Primary Immunodeficiencies
|
| |
August 12, 2008
Talecris Enters into Definitive Merger Agreement with CSL
|
| |
July 24, 2008
Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha-1 Antitrypsin (AAT) From the European Commission
|
| |
June 16, 2008
Talecris Biotherapeutics, Inc. Provides Business Update
|
| |
May 22, 2008
Talecris Biotherapeutics Awarded MedAssets Supply Chain Systems' Platinum Vendor Designation
|
| |
May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
|
| |
May 14, 2008
Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
|
| |
May 08, 2008
FDA Grants Priority Review of Gamunex® as a Treatment for Neurological Disorder CIDP
|
| |
April 28, 2008
Talecris Partners with Catalent Pharma Solutions for European Contract Manufacturing and Product Testing
|
| |
April 07, 2008
Die vom global agierenden Biotechnologieunternehmen Talecris Biotherapeutics, Inc. finanzierte „ICE-Studie“ ist die bislang größte veröffentlichte
|
| |
March 31, 2008
Talecris Biotherapeutics Awarded Manufacturing Contract to Supply Canada with Biological Therapies for the 20th Consecutive Year
|
| |
March 03, 2008
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
|
| |
February 21, 2008
Talecris Biotherapeutics Celebrates 20th Anniversary of Launch of Prolastin®
|
| |
February 13, 2008
Talecris Plasma Resources Reports Solid Progress Developing Plasma Collection Capabilities
|
| |
February 07, 2008
Positive Results from Phase III Trial of Gamunex® in Patients with CIDP
|
| |
January 31, 2008
Prolastin.com Receives Gold Award from Association of Marketing and Communication Professionals
|
| |
January 17, 2008
Precision Pharma Services Merges Into Talecris Biotherapeutics
|
2007 Press Releases
| |
November 12, 2007
www.Prolastin.com Named Best Biotechnology Web Site of 2007
|
| |
October 02, 2007
Talecris Announces New Hypermune™ Product Safety Advances
|
| |
September 18, 2007
Study Demonstrates Aerosolized Prolastin® Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs
|
| |
September 16, 2007
Talecris Biotherapeutics awards Winners of the 4th European ALTA Fellowship Program
|
| |
August 27, 2007
Talecris-Sponsored Scientific Symposium Examines Advances in Use of Intravenous Immune Globulin for Neurological Disorders
|
| |
August 14, 2007
Gamunex® is Now Latex-Free
|
| |
August 08, 2007
Talecris Biotherapeutics Debuts CIDPinfo.com for Neurologists and Healthcare Providers
|
| |
July 11, 2007
New Information on the Potential of Plasmin Shared at ISTH Congress
|
| |
June 12, 2007
Talecris Plasma Resources Supplements Its Collection: Acquisition Adds New Centers
|
| |
May 08, 2007
Talecris Biotherapeutics’ Talents Program Accepting Applications for 2007 Research Grant Awards
|
| |
May 03, 2007
Talecris Provides Educational Grant to Support World Federation of Hemophilia’s Global Laboratory Science Program
|
| |
March 20, 2007
Talecris Initiates Clinical Development Program Evaluating Plasmin for Dissolving Blood Clots and Restoring Blood Flow in Legs
|
| |
February 23, 2007
Gamunex® is the Preferred Liquid IGIV Therapy Among Allergists and Immunologists Surveyed
|
| |
February 15, 2007
Talecris’ Product Integrity Enhanced With Environmentally-friendly Shipping Containers
|
| |
February 13, 2007
Talecris Plasma Resources Opens First New Center in Champaign, Illinois
|
| |
February 01, 2007
Talecris Biotherapeutics supports projects in the field of Alpha-1-Antitrypsin Deficiency with eALTA fellowships
|
| |
January 04, 2007
Talecris Names Inaugural Talents Grant Recipients
|
2006 Press Releases
| |
December 01, 2006
Talecris Continues Global Expansion into Europe
|
| |
November 20, 2006
Talecris Biotherapeutics Completes Acquisition of Plasma Collection Centers
|
| |
November 03, 2006
Talecris Biotherapeutics Named a "Fast 50" Company
|
| |
October 28, 2006
IDF Center of Excellence Dedicated at Duke University
|
| |
October 26, 2006
New Pediatrician Education Program Launched to Increase Awareness and Improve Diagnosis of Immunodeficiencies in Children
|
| |
October 09, 2006
Immune Deficiency Foundation Launches Free Electronic Newsletter
|
| |
October 05, 2006
Talecris Biotherapeutics Celebrates 25 Years of Life-Saving Treatment for People with Primary Immune Deficiency
|
| |
September 05, 2006
Extensive Post-License Data Reaffirm Clinical Safety Profile of Prolastin®
|
| |
September 05, 2006
Pathogen Safety Reconfirmed for Prolastin®
|
| |
September 05, 2006
Talecris Biotherapeutics Awards Third Annual European ALTA Fellowships
|
| |
August 29, 2006
Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use
|
| |
June 28, 2006
Talecris Biotherapeutics Announces Start of Licensing Clinical Trials for Alpha-1 Antitrypsin Using Modified Manufacturing Process
|
| |
May 22, 2006
Landmark Alpha-1 Historical Medical Literature Available from Talecris Biotherapeutics
|
| |
May 03, 2006
Talecris Biotherapeutics Launches Talents: Talecris New Trials Support Program
|
| |
April 03, 2006
Talecris Biotherapeutics Announces Global Expansion
|
| |
January 25, 2006
Grant from Talecris Biotherapeutics Will Support Primary Immunodeficiency Diagnosis and Patient Access to Care
|
2005 Press Releases
| |
November 09, 2005
Talecris Biotherapeutics' Manufacturing Processes Safeguard Against Avian Bird Flu
|
| |
November 04, 2005
Talecris Biotherapeutics Showcases Its Clayton Facility to State and Local Dignitaries
|
| |
October 27, 2005
Talecris Biotherapeutics Strengthens its Executive Leadership Team
|
| |
October 13, 2005
Talecris Celebrates the Second Anniversary of Gamunex®
|
| |
October 13, 2005
Talecris Biotherapeutics Initiates Voluntary Recall of Plasmanate®
|
| |
October 04, 2005
Talecris Biotherapeutics Receives QSEAL Certification from PPTA
|
| |
September 27, 2005
Talecris Biotherapeutics Awards Second Annual ALTA Fellowships
|
| |
August 18, 2005
Talecris Announces Extended Room Temperature Storage for Gamunex®
|
| |
August 09, 2005
Talecris Biotherapeutics and BBI Sign Development Agreement for Alpha-1 Antitrypsin Test
|
| |
July 07, 2005
Labeling for Gamunex® now Includes Assurances of Removal of Pathogenic Prions During Manufacture
|
| |
June 16, 2005
Talecris Biotherapeutics Reaffirms Commitment to Set Industry Standard for Product Integrity
|
| |
May 26, 2005
Talecris Biotherapeutics Becomes First Plasma Fractionator to Perform In-house HBV Screening Using FDA-Licensed Protocol
|
| |
April 28, 2005
An Evening Symposium held during the European Respiratory Society Annual Congress 2005, Copenhagen
|
| |
April 01, 2005
Announcing the Launch of Talecris Biotherapeutics: Combining a Proud History of Patient Care with a Bold New Vision
|
| |
January 07, 2005
Bausch & Lomb To License Plasmin from Bayer HealthCare for Ophthalmic Use
|
|
|
|
|
|
|
|
|
